Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma.
Annekatrin SeidlitzBettina Beuthien-BaumannSteffen LöckChristina JentschIvan PlatzekKlaus ZöphelAnnett LingeJörg KotzerkeJan PetrJörg van den HoffJörg SteinbachDietmar KrexGabriele Schmitz-SchackertMonique FalkMichael BaumannMechthild KrausePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Postsurgical amino acid PET has prognostic value for TTR after RCT in glioblastoma. Because of the added value of the metabolic beyond the pure structural information, it should complement MRI in radiotherapy planning if available with reasonable effort, at least in the context of maximal therapy. Furthermore, the spatial correlation of regions of recurrence with PET-positive volumes could provide a bioimaging basis for further trials, for example, testing local radiation dose escalation.
Keyphrases
- computed tomography
- pet ct
- positron emission tomography
- contrast enhanced
- magnetic resonance imaging
- pet imaging
- amino acid
- locally advanced
- early stage
- clinical trial
- study protocol
- quantum dots
- randomized controlled trial
- squamous cell carcinoma
- healthcare
- phase iii
- heart rate
- stem cells
- phase ii
- resistance training
- magnetic resonance
- mesenchymal stem cells
- bone marrow
- high intensity
- cell therapy